# PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

> **NCT06048302** · PHASE1 · COMPLETED · sponsor: **NewAmsterdam Pharma** · enrollment: 18 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy

## Interventions

- **DRUG:** Obicetrapib

## Key facts

- **NCT ID:** NCT06048302
- **Lead sponsor:** NewAmsterdam Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-30
- **Primary completion:** 2024-03-12
- **Final completion:** 2024-03-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06048302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06048302, "PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06048302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*